We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.0545 | -0.39% | 14.0255 | 14.16 | 14.00 | 14.15 | 4,873,511 | 20:03:28 |
From May 2019 to May 2024
By Chris Wack
The U.S. Food and Drug Administration on Monday said it approved multiple applications for the first generics of Lyrica, or pregabalin, for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and neuropathic pain associated with spinal cord injury.
The FDA granted approvals for the generic versions of Lyrica to Alembic Pharmaceuticals (533573.BY), Alkem Laboratories (539523.BY), Amneal Pharmaceuticals (AMRX), Dr. Reddy's Laboratories (RDY), InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals (TEVA).
The FDA said the approval of the first generics for pregabalin advances patient access to lower cost, high-quality generic medicines.
The most common side effects reported in the clinical trials for Lyrica in adults are dizziness, somnolence, dry mouth, swelling, blurred vision, weight gain and abnormal thinking.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 22, 2019 11:21 ET (15:21 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
